Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma

NCT01196416 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

14

Enrollment

NIH

Sponsor class

Conditions

Recurrent Melanoma
Stage IV Skin Melanoma

Interventions

DRUG: Cisplatin
DRUG: Gamma-Secretase Inhibitor RO4929097
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
DRUG: Temozolomide
DRUG: Vinblastine Sulfate

Sponsor

National Cancer Institute (NCI)